van Velthuijsen Eveline L, Zwakhalen Sandra M G, Pijpers Evelien, van de Ven Liesbeth I, Ambergen Ton, Mulder Wubbo J, Verhey Frans R J, Kempen Gertrudis I J M
Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands.
Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Drugs Aging. 2018 Feb;35(2):153-161. doi: 10.1007/s40266-018-0523-9.
Delirium in older hospitalised patients is a common and serious disorder. Polypharmacy and certain medications are risk factors for developing delirium. A medication review could benefit older hospitalised patients with delirium.
(1) Evaluate the effects of medication review on length of delirium, length of hospital stay, mortality, and discharge destination; and (2) describe and analyse the proposed changes to medication and its implementation by the treating physician.
The study was conducted at Maastricht University Medical Centre+.
We compared two cohorts of older patients with delirium: the first cohort from before introducing the medication review, and a second cohort 5 months after introduction of the medication review. Data were extracted from the patients' digital medical records.
A significant interaction effect of cohort and number of medications taken by the patient was found for duration of delirium: patients from the second cohort taking between zero and six medications had significantly shorter delirious episodes than patients in the first cohort. This effect bordered on significance for patients taking between seven and 11 medications, but disappeared for patients taking 12 or more medications. No other statistically significant differences were found between the cohorts. The proposed changes in medication were implemented for 71% of the patients.
A medication review seems to significantly decrease the length of an older patient's delirious episode. Given the clinical relevance of these findings, we advise medication reviews for all older patients who are delirious or are at risk of developing delirium.
老年住院患者谵妄是一种常见且严重的疾病。多重用药及某些药物是发生谵妄的危险因素。药物审查可能使患有谵妄的老年住院患者受益。
(1)评估药物审查对谵妄持续时间、住院时间、死亡率及出院目的地的影响;(2)描述并分析治疗医生提议的药物变更及其实施情况。
该研究在马斯特里赫特大学医学中心+进行。
我们比较了两组患有谵妄的老年患者队列:第一组来自引入药物审查之前,第二组来自引入药物审查5个月后。数据从患者的数字医疗记录中提取。
在谵妄持续时间方面,发现队列与患者服用药物数量之间存在显著的交互作用:第二组中服用0至6种药物的患者谵妄发作时间明显短于第一组患者。对于服用7至11种药物的患者,这种影响接近显著水平,但对于服用12种或更多药物的患者则消失。两组之间未发现其他具有统计学意义的差异。71%的患者实施了提议的药物变更。
药物审查似乎能显著缩短老年患者的谵妄发作时间。鉴于这些发现的临床相关性,我们建议对所有患有谵妄或有发生谵妄风险的老年患者进行药物审查。